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Abstract: Head and neck cancer is one of the most commonly diagnosed malignancies 
worldwide. Patients with advanced disease stages frequently develop recurrences or distant 
metastasis, which results a five-year survival rates of less than 60% despite considerable 
advances in multimodality therapy. A better understanding of molecular basis of 
tumorigenesis is required to improve clinical outcomes and to develop new anti-cancer 
drugs. microRNAs (miRNAs) are a class of small, non-coding, RNA molecules that 
modulate gene expression post-transcriptionally. They are important regulator in normal 
biological process; however miRNAs deregulation has been observed in many different 
tumors and is involved in tumorigenesis. miRNAs may act as tumor suppressors or as 
oncogenes. Several studies on head and neck cancer demonstrated how aberrant expression 
of miRNAs is involved in proliferation, metastasis, chemoresistence, and radioresistance. 
In addition, miRNAs are excellent biomarker targets because they circulate stable in 
human body fluids and can be obtained with non-invasive methods. Moreover, miRNAs up 
and down regulation has been correlated with specific cancer phenotype (poor prognosis, 
aggressiveness and resistance to treatment), playing a role as prognostic biomarkers. This 
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review summarizes current finding on miRNAs in head and neck cancer and their potential 
role as target for next drug therapy. 
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1. Introduction 
Head and neck cancer (HNC) is a heterogeneous oncological setting arising from oral and nasal 
cavities, pharynx or larynx. It is the sixth most common cancer worldwide. The incidence of HNC in 
the European Union for 2012 was estimated in 73,014 new cases/year: Germany, France and Denmark 
showed the highest risk [1]. Squamous cell carcinoma is the most common histologic type (more than 
90% of cases). Adenocarcinoma, basal cell and small cell, lymphomas, sarcomas and others are 
uncommon. Chronic tobacco, alcohol abuse and Human Papilloma-Virus (HPV) infection are the main 
risk factors for the development of squamous-cell HNC (SCHNC). In patients presenting with early, 
localized disease, surgery or radiotherapy achieve cure in the large majority of cases. Locally advanced 
disease is usually treated using integrated treatment modalities including chemotherapy with a worse 
long-term prognosis. Patients with loco-regional relapse or metastatic disease might benefit from 
palliative chemotherapy but usually cannot be cured. 
Inactivation of tumor suppressor genes (e.g., p53, p16inK4a), activation of proto-oncogenes  
(e.g., cyclin D, Rb) and enhanced expression of the epidermal growth factor receptor (EGFR) have 
been observed in SCHNC [2]. Cetuximab, an anti-EGFR monoclonal antibody, has demonstrated 
activity when combined with radiotherapy in locally advanced disease [3] and in combination with 
chemotherapy in the relapsed/metastatic setting [4], and has been approved for the treatment of 
SCHNC [5]. On-going clinical trials are evaluating the efficacy of others EGFR monoclonal antibodies 
(panitumumab, zalutumumab) and EGFR tyrosine kinase inhibitors (gefitinib, lapatinib, afatinib, 
erlotinib) in these patients [6]. Despite the improvement of surgery, chemotherapy and radiotherapy, 
the 5-year survival rates are less than 60% [7]. In the last years, increasing interest has been focused  
on the role of microRNA (miRNA) in cancer. As in others malignancies, miRNA regulates several 
oncogenes and tumor suppressors, driving the growth, proliferation, metastatic attitude and drug 
resistance also. 
2. miRNA 
miRNAs are a large family of high conserved non-coding, double-stranded RNA, consisting of 
about 18–25 nucleotides, that are able to regulate expression of multiple target genes in normal 
biological process (such as proliferation, differentiation and apoptosis) at post-transcriptional level. To 
date, 1,872 different miRNAs have been identified in human and the number is still rising [8]. 
miRNA genes are transcribed by RNA polymerase II (Poll) to form primary miRNA (pri-mRNA) 
characterized by a specially modified nucleotide at the 5ʹend and a polyadenilated at the 3ʹend (Figure 1). 
The Microprocessor Complex, formed by a nuclear protein known as DiGeorge Syndrome Critical 
region 8 (DGCR8) and an enzyme called Drosha ribonuclease (RNase III), convert pri-mRNAs  
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into a second precursor (pre-miRNA) [9,10]. This is then transported into cytoplasm through  
Ran-GTP-dependent transporter Exportin-5 where it is cleaved by the RNase III enzyme Dicer to 
create a miRNA-miRNA duplex. In order to form the final complex that performs gene silencing, the 
double-strained needs to be separated into the functional strand and loaded together with Argonaute 
proteins into the RNA-induced silencing complex (RISC). This complex mediates gene expression by 
binding target mRNAs and inducing mRNA degradation [11]. Several studies reported aberrantly 
expression of miRNAs in several cancers, where they play a role as tumor suppressors or as oncogenes. 
Up-regulation of oncogenic miRNAs results in down-regulation of tumor suppressor genes whereas 
down-regulation of tumor suppressive miRNAs results in up-regulation of oncogenes [12]. 
Endogenous circulating miRNAs are stable, and are protected from RNases, remaining steady even 
after being subjected to unfavourable conditions [13]. 
Figure 1. MiRNA biogenesis. MiRNAs genes are transcribed by RNA polymerase into 
primary miRNAs (pri-miRNA). They are converted into second precursors (pre-miRNA) 
by the Microprocessor Complex, composed by DiGeorge Syndrome Critical region 8 
(DGCR8) and Drosha ribonuclease (RNase III). They are then exported to the cytoplasm 
by Exportin 5 and are processed into mat ure miRNA/miRNA duplex by DICER enzyme. 
One of the strands is combined with Argonaute proteins (Ago2) to RNA Induced Silencing 
Complex (RISC). This complex mediates gene expression by binding target mRNAs and 
inducing mRNA degradation. 
 
miRNAs were discovered in 1993, within Ambros and Ruvhun’s lab, on Caenorhabditis elegans. 
An intense research started in the following years aimed at understanding miRNAs functions and 
possible applications. miRNAs are implicated in several biological and pathologic processes. Great 
effort is focused on explanation of the potential role of miRNAs in inflammatory disease, atherosclerosis, 
metabolic disease and fibrosis [14]. They are also important regulator of immune system and 
angiogenesis. Moreover, miRNA involvement in tumorigenesis was demonstrated by the development 
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of lymphoproliferative tumors in transgenic mouse whose miR-155 gene was up-regulated [15]. As in 
hematologic neoplasms, solid tumors show aberrant expression of several miRNAs. 
3. miRNA Deregulation in Head and Neck Cancers 
A summary of recent studies regarding miRNA expression profiling in SCHNC is shown in  
Table 1 [16–37]. The vast majority of studies included a slender number of cases and informations  
are not conclusive yet. miR-21 has been shown to act as an oncogene by targeting PTEN in various 
cancer [38,39]. The miR-21 has also been frequently observed in HNC as reported in Table 1. Recent 
studies on SCHNC demonstrated that increased expression of miR-21 causes reduction of PTEN 
expression [27] and its transcriptional regulator Grhl3 [40]. PTEN is an inhibitor of the PI3K pathway. 
Its inactivation leads to accumulation of phosphatidylinositol 3,4,5-triphosfate (PIP3) and consequently 
increased activity of serine/threonine protein kinase PDK-1 and AKT which promote cell cycle 
progression, proliferation and inhibit apoptosis. miR-31 activates the hypoxia-inducible factor (HIF) 
pathway through the suppression of its inhibitors factors (FIH), consequently promoting tumor 
angiogenesis and growth. As in other cancers, deregulation of miR-31 was observed in SCHNC [28,36]. 
miR-375 is frequently found as down-regulated in SCHNC and acts as tumor suppressor. Hui et al. 
demonstrated that the down-regulation of miR-375, observed in over 91% of HNSCC samples, would 
result in deregulated proliferation, chaotic growth and inhibited apoptosis [24]. Moreover, Nohata et al. 
suggested that miR-375 acts as tumor suppressor and regulates AEG1/MTDH (astrocyte elevated gene 
1/metadherin), a mediator in different signaling pathways such PI3k/AK, NF-Kb and Wnt/b-catenin, 
promoting oncogenesis [30]. 
Table 1. miRNA expression profiling in SCHNC recent studies. 
Reference Materials Methods miRNA Deregulation 
Avissar  
et al. [16] 
16 tumors, 5 normal 
microRNA 
array 
↑ miR-21, miR-181d, miR-181b, miR-491, miR-455, miR-455, 
miR-18a, miR-130b, miR-221, miR-193b, miR-181a, miR-18b ↓ 
miR-375 
Barker  
et al. [17] 






↑ miR-103, miR-155, miR-191, miR-181b, miR-181d, miR-205 
Cao  
et al. [18] 




↑ miR-125, miR-145 ↓ miR-93, miR-205, miR-21, miR-708 
Cervigne  
et al. [19] 




↑ miR-21, miR-181b, miR-345, miR-146a, miR-184, miR-518b, 
miR-520g, miR-649  
Chang  
et al. [20] 
8 tumors, 4 normal 
microRNA 
array 
↑ miR-21, miR-155, miR-146, miR-29c, miR-18, miR-146b, let-7i, 
miR-142-3p ↓ miR-494 
Childs  
et al. [21] 
8 tumors, 8 normal 
MicroRNA 
array 
↑ miR-21, miR-24, miR-151, miR21, miR-199b ↓ let-7f,  
miR-142-3p, miR-324-5p, miR-368, miR-370, miR-373,  
miR-422b, miR-424, miR-95, let-7a, miR-16-2, miR-1, miR-133a 
Christensen 
et al. [22] 





↓ Let-7 family 
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Table 1. Cont. 
Reference Materials Methods miRNA Deregulation 
Fletcher  
et al. [23] 
19 tumors, 7 normal qRT-PCR ↑ miR-205 
Hui et al. 
[24] 




↑ miR-423, miR-93, miR-106b, miR-16, miR-20a, miR-155,  
miR-193a, miR-25, miR-92, miR-17-5p, let-7i, miR-19b, miR-223, 
miR-27a, miR-142-3p, miR-210, miR-106a, miR-15a, miR-21, 
miR-29b, miR-130b, miR-205, miR-422b ↓ miR-125b, miR-375, 
miR-10a, let-7a, miR-140, miR-100, miR-143, miR-99a, miR-30c, 
miR-365, miR-127, let-7c, miR-199b, let-7e, miR-26a 
Kozaki  
et al. [25] 
18 tumors, 1 normal qRT-PCR 
↑ miR-374, miR-340, miR-224, miR-10a, miR140, miR-181a ↓ 
miR-27a, miR-34b, miR-34c, miR-203, miR-302c, miR-23a,  
miR-27b, miR-34a, miR-215, miR-299, miR-330, miR-337,  
miR-107, miR-133b, miR-138, miR-139, miR-223, miR-204,  
miR-370, let-7d, mir-95, miR-302a, miR-367* 
Lajer  
et al. [26] 




↑ miR-31, miR-21, miR-223, miR-503, miR-187, miR-1246,  
miR-146b-5p, miR-146a, miR-155, miR-424, miR-181a,  
miR-181b, miR-27a, miR-132, miR-106b, miR-345, miR-21 ↓ 
miR-375, miR-1224-5p, miR-617, miR-99a, miR-125b, miR-378, 
miR-27b, miR-125b-2 
Li  
et al. [27] 






et al. [28] 





↑ mir-31, miR-34c, miR-187, miR-135b, miR-372, miR-34b, miR-21, 
miR-371, miR-216, miR-301, miR-10a, miR-155, miR-130b,  
miR-223, miR-373, miR-96, miR-224, miR-147, miR-128b,  
miR-104, miR-183, miR-182 ↓ miR-100, miR-328, miR-99a,  
miR-124, miR-149, miR-139, miR-124a, miR-204, miR-211 
Kikkawa  
et al. [29] 





↑ miR-517c, miR-196a, miR-7, miR-196b, miR-650, miR-18a, 
miR-452, miR-183, miR-432, miR-301a, miR-21 ↓ miR-1,  
miR-375, miR-139-5p, miR-504, miR-125b, miR-199b, miR-100, 
miR-497, miR-30a, let-7c, miR-218, miR-10b, miR-126, miR-378, 
miR-328, miR-204, miR-143, miR-126, miR-99a, miR-195,  
miR-489, miR-203, miR-140-5p, miR-29a, miR-26a, miR-214, 
miR-30a, miR-26b, miR-30e, miR-30b, let-7b 
Nohata  
et al. [30] 




↓ miR-874, miR-133a, miR-375, miR-204, miR-1, miR-139-5p, 
miR-145, miR-143, miR-486-3p, miR-146a, miR-410, miR-126, 
miR-539, miR-134, miR-218, miR-146b-5p, miR-140-3p,  
miR-30a-3p, miR-191, miR-186, miR-148a, miR-30e-3p, miR-29c* 
Ramdas  
et al. [31] 
5 Tumors, 5 normal  
microRNA 
array 
↑ miR-7083, miR-7, miR-34b, miR-155, miR-182, miR-21,  
miR-181c, miR-181a, miR-25, miR-93, let-7i, miR-107, miR-103, 
miR-221 ↓ miR-23b, miR-7029, miR-125a, miR-125b 
Rentoft  
et al. [32] 
21 tumors, 8 normal 
microRNA 
array 
↑ miR-424, miR-21, miR-1301, miR-7, miR-142-5p, miR-105, 
miR-142-3p, miR-146b-3p, miR-659, miR-361-3p, miR-665,  
miR-146 b-5p* ↓ miR-617, miR-29b-2, miR-132, miR-548b-5p, 
miR-22, miR-629, mir-29b-1, miR-99a, let-7c* 
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Table 1. Cont. 
Reference Materials Methods miRNA Deregulation 
Scapoli  




↑ miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92,  
miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338 
↓ miR-520h, miR-197, miR-378, miR-135b, miR224, mir-34a 
Tran  




↑ miR-21, miR-205, miR-16, let-7a ↓ miR-342, miR-346, miR-373 
Wiklund  
et al. [35] 
15 tumors, 7 normal qRT-PCR ↑ miR-127, miR-200, miR-205 ↓ miR-375, miR-137 
Wong  
et al. [36] 




↑ miR-184, miR-34c, miR-137, miR-372, miR-124a, miR-21, 
miR-124b, miR-31, miR-128a, miR-34b, miR-154, miR-197,  
miR-132, miR-147, miR-325, miR-181c, miR-198, miR-155,  
miR-30a-3p, miR-338, miR-17-5p, miR-104, miR-134, miR-213 ↓ 
miR-133a, miR-99a, miR-194, miR-133b, miR-219, miR-100, 
miR-125b, miR-26b, miR-138, miR-149, miR-195, miR-107,  
miR-139 
Xiao  
et al. [37] 






↑ miR-31, miR-142-5p, miR-33a, miR-1259, miR-146b-5p,  
miR-886-3p, miR-886-5p, miR-519d, miR-301a ↓ miR-572, miR-611, 
miR-602, miR-675, miR-585, miR-623, miR-637, miR-1184 
4. miRNAs as Prognostic Indicators 
The prognosis of advanced SCNHC is dismal despite improvements in multimodal treatment. 
Recent studies showed a potential role of miRNAs as prognostic biomarkers. 
Let-7 is a family of tumor suppressing miRNAs whose levels were found deregulated in SCHNC by 
different authors ([21–33] and others). Moreover Scapoli et al. [33] found a correlation between 
underexpression of Let-7, miR-155 and miR-146a and progression to metastatic tumors. 
In a study on nasopharyngeal carcinoma cells, Wong et al. found low levels of Let-7 miRNA and 
suggested a role in regulating proliferation through the downregulation of c-MYC expression [41]. 
Low levels of Let-7 have a proliferative effect on nasopharyngeal cells trough the unsuccessful 
suppressing effect on c-MYC expression. 
Moreover, recent studies on non-small cell lung cancer highlighted the role of Let-7 in the KRAS 
regulation [42]. A variant allele in the KRAS 3ʹ untranslated region, that binds the let-7 complementary 
site (KRAS-LCS6), is associated with an increased KRAS expression and low levels of Let-7. 
Christensen et al. demonstrated the presence of KRAS-LCS6 variant in SCHNC and its correlation 
with poor prognosis, especially in oral cancer [22]. 
TP53 is a tumor suppressor gene encoding for a protein that regulates the cell cycle. TP53 mutation 
is a common alteration in cancer with a frequency of 53% found in a large cohort of SCHNC analyzed 
by Poeta et al. TP53 mutations were more frequently in patients with tumors arising from hypopharynx 
(75%) and larynx (56.7%). Moreover, authors demonstrated a strong correlation between TP53 
mutations in SCHNC and high risk of recurrence and poor survival [43]. Ganci et al. [44] found a 
strong association between 49 miRNAs and TP53 status with a particular correlation of a subset of  
12 miRNAs with shorter recurrence free-survival whereas 4 of them were associated with lower 
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cancer-specific survival. A correlation between the expression of specific miRNAs, such as miR-375 
and miR-210, and outcome of SCHNC patients was indeed reported: low levels of miR-375 correlated 
with poor survival and distant metastases as high levels of miR-210 correlated with locoregional 
recurrence [45,46]. 
5. miRNAs as Biomarkers 
SCHNC is frequently diagnosed in advanced stage when metastases to regional lymph nodes are 
already present. Even with combination of surgery, chemotherapy and radiotherapy, these patients 
have a high risk of recurrence. Thus, an important goal would be the identification of biomarkers for 
early detection. Recent studies identified a potential role of some miRNAs as diagnostic biomarkers. 
Actually, miRNAs circulate stably in different human body fluids, such as blood, saliva, urine and 
breath. Hence they can be accessible with non-invasive methods. 
Wong et al. detected the presence of miR-184 in the plasma of 80% of patients with tongue 
squamous cancer (all stages) compared to 13% of healthy patients [36]. In the saliva of patients with 
oral squamous cell cancer, miR-125a and miR-200 were significantly under expressed compared to 
controls [47]. Moreover, Liu et al. showed high levels of salivary miR-31 in oral cancer while levels of 
miR-31 in plasma were up-regulated [48,49]. Lastly, Clague et al. reported the correlation between one 
variant allele of miR-26a and an increased risk to develop premalignant oral lesions [50]. 
6. miRNAs and Resistance to Chemotherapy and Radiotherapy 
The combination of chemotherapy and radiotherapy is the standard treatment for locally advanced 
SCHNC. However resistance to anticancer drugs oftenly leads to treatment failure, though alterations 
of different molecular pathways. Recent studies hypothesized a potential role of miRNAs in 
chemoresistance. Yu et al. found a different expression of miRNAs between cisplatin-sensitive tongue 
squamous cell carcinoma and cisplatin-resistant sublines: in particular increased levels of let-7 family, 
miR-23a, miR-214, miR-518c, miR-608 and decreased levels of miR-21 and miR-342 [51]. miR-21 
and miR-214 have been already reported to alter the chemosensitivity in others tumors as 
cholangiocarcinoma and ovarian cancer respectively [52,53]. In this study, miR-214 might induce cell 
survival and cisplatin resistance through targeting the 3’-untranslated region (UTR) of the PTEN gene, 
which leads to down-regulation of the protein and activation of Akt pathway. 
Several authors have also investigated the role of miRNAs in the development of radioresistance. 
miRNA expression profiles have been compared in 6 tumors cell lines (3 from gliomas and 3  
from squamous cell carcinomas) after ionizing radiation. Levels of miR-24-1, miR-144, let-7i, and 
miR-1285 were significantly increased following irradiation, confirming their susceptibility to ionizing 
radiation [54]. miR-205 has been investigated in a radio-resistant nasopharyngeal carcinoma cell line 
(CNE-2P). High level of miR-205 has been detected compared to cell line control [55]. The 3’-UTR of 
PTEN contains a binding site for miR-205. PTEN is largely known as an inhibitor of cell cycle 
progression. Authors suggested that PTEN is responsible for radioresistance through miR-205. Low 
levels of miR-125b, observed in oral squamous cell carcinoma cells, are correlated with proliferation 
and radioresistance mechanism, mediated by the downregulation of the intracellular adhesion molecule 
2 (ICAM2) [56]. Actually, miR-125b has complementary sequences for ICAM2 mRNA. 
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7. The Application of miRNA to Cancer Treatment 
One key possibility for the future is the modulation of altered miRNAs concentration through 
molecules that replace downregulated miRNAs or using antagonists that binds overexpressed 
miRNAs. The first clinical trial, using a complementary molecule, was conducted in patients with 
chronic HCV infection [57]. Miravirsen is a short oligonucleotide that binds and inhibits miR-122. 
miR-122 is highly expressed in the liver and enhances HCV propagation. An ongoing phase II trial has 
the purpose to assess the antiviral activity and safety of Miravirsen. 
To our knowledge there is only one clinical trial available in cancer patients. MRX34 is a molecule 
mimicking miR-34, which is found as downregulated in many tumors. miR-34 inhibits cancer 
proliferation and apoptosis by the deregulation of MYC, MET, BCLR and β-catenin. A phase I 
ongoing study is evaluating the maximum tolerate dose and the pharmacokinetic of MRX34 in patients 
with primary liver cancer or liver metastasis [58]. 
8. Conclusions 
It is widely recognized that miRNAs are pivotal pawns in the cancer development of many tumors, 
including HNC. Several studies demonstrated considerable discrepancies in miRNAs levels between 
tumors and corresponding adjacent normal tissues. Moreover, a change in miRNAs expression has 
been observed in primary disease compared to metastatic sites, suggesting a role in the tumor 
progression. miRNAs are easily obtained with non-invasive methods because they circulate stable in 
blood, urine and saliva. Further studies will be needed to identify specific miRNAs that can be used as 
biomarkers for early detection or as biomarkers with predictive value. However, to date, there are no 
data mature enough to introduce miRNAs expression analysis in the current clinical management. 
From a therapeutic point of view, miRNA-based therapies are currently in preclinical and clinical 
development with encouraging results. For miRNAs whose expression is reduced, re-introduction of 
mimics miRNAs could restore the correct gene targets modulation. Conversely, for miRNAs whose 
expression is increased, the strategy is aimed to the inhibition through use of anti-miRNAs. 
Author Contributions 
Giulia Courthod and Gianmauro Numico: study concept and design; Pierfrancesco Franco, 
Loredana Palermo and Salvatore Pisconti: acquisition of literature data; Giulia Courthod, Gianmauro 
Numico, Pierfrancesco Franco, Loredana Palermo and Salvatore Pisconti: data analysis and 
interpretation; Giulia Courthod and Gianmauro Numico: drafting of the manuscript. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.; Comber, H.; 
Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for  
40 countries in 2012. Eur. J. Cancer 2013, 49, 1374–1403. 
Molecules 2014, 19 5712 
 
2. Perez-Ordonez, B.; Beauchemin, M.; Jordan, R.C. Molecular biology of squamous cell carcinoma 
of the head and neck. J. Clin. Pathol. 2006, 59, 445–453. 
3. Bonner, J.A.; Harari, P.M.; Giralt, J.; Cohen, R.B.; Jones, C.U.; Sur, R.K.; Raben, D.; Baselga, J.; 
Spencer, S.A.; Zhu, J.; et al. Radiotherapy plus cetuximab for locoregionally advanced head  
and neck cancer: 5-year survival data from phase 3 randomised trial, and relation between 
cetuximab-induced rash and survival. Lancet Oncol. 2010, 11, 21–28. 
4. Vermorken, J.B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawwecki, A.; Rottey, S.; Erfan, J.; 
Zabolotnyy, D.; Kienzer, H.; Cupissol, D.; et al. Platinum-Based Chemotherapy plus Cetuximab 
in Head and Neck Cancer. N. Engl. J. Med. 2008, 359, 1116–1127. 
5. Numico, G.; Franco, P.; Cristofano, A.; Migliaccio, F.; Spinazzé, S.; Silvestris, N.; Cante, D.; 
Sciacero, P.; la Porta, M.R.; Girelli, F.; et al. Is the combination of Cetuximab with  
chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck 
cancer? A review of current evidence. Crit. Rev. Oncol./Hematol. 2013, 85, 112–120. 
6. Numico, G.; Silvestris, N.; Grazioso Russi, N. Advances in EGFR-directed therapy in head and 
neck cancer. Front. Biosci. 2011, 3, 454–466. 
7. Leemans, C.R.; Braakhuis, B.J.M.; Brakenhoff, R.H. The molecular biology of head and neck 
cancer. Nat. Rev. Cancer 2011, 11, 9–22. 
8. Homo Sapiens miRNA (1872 Sequences). Available online: http://www.mirbase.org/cgi-
bin/mirna_summary.pl?org=hsa (accessed on 21 March 2014). 
9. Lee, Y.; Kim, M.; Han, J.; Yeom, K.H.; Lee, S.; Baek, S.H.; Kim, V.N. microRNA genes are 
transcribed by RNA polymerase II. EMBO J. 2004, 23, 4051–4060. 
10. Cai, X.; Hagedorn, C.H.; Cullen, B.R. Human microRNAs are processed from capped, 
polyadenylated transcripts that can also function as mRNAs. RNA 2004, 10, 1957–1966. 
11. Kwak, P.B.; Iwasaki, S.; Tomari, Y. The microRNA pathway and cancer. Cancer Sci. 2010, 101, 
2309–2315. 
12. Garzon, R.; Calin, G.A.; Croce, C.M. microRNAs in cancer. Annu. Rev. Med. 2009, 60, 167–179. 
13. Hu, Z.; Chen, X.; Zhao, Y.; Tian, T.; Jin, G.; Shu, Y.; Chen, Y.; Xu, L.; Zen, K.; Zhang, C.; et al. 
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling 
predict survival of non-small cell lung cancer. J. Clin. Oncol. 2010, 28, 1721–1726. 
14. Van Rooij, E.; Purcell, A.L.; Levin, A.A. Developing microRNA therapeutics. Circ. Res. 2012, 
110, 496–507. 
15. Costinean, S.; Zanesi, N.; Pekarsky, Y.; Till, E.; Volinia, S.; Heerema, N.; Croce, C.M. Pre-B cell 
proliferation and lymphoblastic leukemia/high-grade lymphoma in Eµ-miR155 transgenic mice. 
Proc. Natl. Acad. Sci. USA 2006, 103, 7024–7029. 
16. Avissar, M.; Christensen, B.C.; Kelsey, K.T.; Marsit, C.J. microRNA expression ratio is 
predictive of head and neck squamous cell carcinoma. Clin. Cancer Res. 2009, 15, 2850–2855. 
17. Barker, E.V.; Cervigne, N.K.; Reis, P.P.; Goswami, R.S.; Xu, W.; Weinreb, I.; Irish, J.C.;  
Kamel-Reis, S. microRNA evaluation of unknown primary lesions in the head and neck.  
Mol. Cancer 2009, 8, 127. 
   
Molecules 2014, 19 5713 
 
18. Cao, P.; Zhou, L.; Zhang, J.; Zheng, F.; Wang, H.; Ma, D.; Tian, J. Comprehensive expression 
profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck 2013, 35, 720–728. 
19. Cervigne, N.K.; Reis, P.P.; Machado, J.; Sadikovic, B.; Bradley, G.; Galloni, N.N.; Pintilie, M.; 
Jurisica, I.; Perez-Ordonez, B.; Gilbert, P.; et al. Identification of a microRNA signature associated 
with progression of leukoplakia to oral carcinoma. Hum. Mol. Genet. 2009, 18, 4818–4829. 
20. Chang, S.S.; Jiang, W.W.; Smith, I.; Poeta, L.M.; Begum, S.; Glazer, C.; Shan, S.; Westra, W.; 
Sidransky, D.; Califano, J.A. microRNA alterations in head and neck squamous cell carcinoma. 
Int. J. Cancer 2008, 123, 2791–2797. 
21. Childs, G.; Fazzari, M.; Kung, G.; Kawachi, N.; Brandwein-Gensler, M.; McLemore, M.; Chen, Q.; 
Burk, R.D.; Smith, R.V.; Prystowsky, M.B.; et al. Low-level expression of microRNAs let-7d and 
miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am. J. Pathol. 2009, 
174, 736–745. 
22. Christensen, B.C.; Moyer, B.J.; Avissar, M.; Ouellet, L.G.; Plaza, S.L.; McClean, M.D.;  
Marsit, C.J.; Kelsey, K.T. A let-7 microRNA-binding site polymorphism in the KRAS 30 UTR is 
associated with reduced survival in oral cancers. Carcinogenesis 2009, 30, 1003–1007. 
23. Fletcher, A.M.; Heaford, A.C.; Trask, D.K. Detection of metastatichead and neck squamous cell 
carcinoma using the relative expres-sion of tissue-specific miR-205. Transl. Oncol. 2008, 1,  
202–208. 
24. Hui, A.B.Y.; Lenarduzzi, M.; Krushel, T.; Waldron, L.; Pintilie, M.; Shi, W.; Perez-Ordonez, B.; 
Jurisica, I.; O’sullivan, B.; Waldrom, J.; et al. Comprehensive microRNA profiling for head and 
neck squamous cell carcinomas. Clin. Cancer Res. 2009, 16, 1129–1139. 
25. Kozaki, K.; Imoto, I.; Mogi, S.; Omura, K.; Inazawa, J. Exploration of tumor-suppressive 
microRNAs silenced by DNA hypermethylationin oral cancer. Cancer Res. 2008, 68, 2094–2105. 
26. Lajer, C.B.; Nielsen, F.C.; Friis-Hansen, L.; Norrild, B.; Borup, R.; Garnaes, E.; Rossing, M.; 
Specht, L.; Therkildsen, M.H.; Nauntofte, B.; et al. Different miRNA signatures of oral and 
pharyngeal squamous cell carcinomas: A prospective translational study. Br. J. Cancer 2011, 104, 
830–840. 
27. Li, J.; Huang, H.; Sun, L.; Yang, M.; Pan, C.; Chen, W.; Wu, D.; Lin, Z.; Zeng, C.; Yao, Y.; et al. 
miR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. 
Clin. Cancer Res. 2009, 15, 3998–4008. 
28. Liu, C.J.; Tsai, M.M.; Hung, P.S.; Kao, S.Y.; Liu, T.Y.; Wu, K.J.; Chiou, S.H.; Lin, S.C.;  
Chang, K.W. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF 
pathway in head and neck carcinoma. Cancer Res. 2010, 70, 1635–1644. 
29. Kikkawa, N.; Hanazawa, T.; Fujimura, L.; Nohata, N.; Suzuki, H.; Chazono, H.; Sakurai, D.; 
Horiguchi S.; Okamoto, Y.; Seki, N. miR-489 is a tumour-suppressive miRNA target PTPN11 in 
hypopharyngeal squamous cell carcinoma (HSCC). Br. J. Cancer 2010, 103, 877–884. 
30. Nohata, N.; Hanazawa, T.; Kikkawa, N.; Sakurai, D.; Fujimura, L.; Chiyomaru, T.; Kawakami, K.; 
Yoshino, H.; Enokida, H.; Nakagawa, M.; et al. Tumour suppressive microRNA-874 regulates 
novel cancer networks in maxillary sinus squamous cell carcinoma. Br. J. Cancer 2011, 105,  
833–841. 
Molecules 2014, 19 5714 
 
31. Ramdas, L.; Giri, U.; Ashorn, C.L.; Coombes, K.R.; El-Naggar, A.; Ang, K.K.; Story, M.D. 
miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal 
tissue. Head Neck 2009, 31, 642–654. 
32. Rentoft, M.; Fahlen, J.; Coates, P.J.; Laurell, G.; Sjostrom, B.; Ryden, P.; Nylander, K. miRNA 
analysis of formalin-fixed squamous cell carcinoma of the tongue is affected by age of the 
sample. Int. J. Oncol. 2011, 38, 61–69. 
33. Scapoli, L.; Palmieri, A.; Lo Muzio, L.; Pezzetti, F.; Rubini, C.; Girardi, A.; Farinella, F.; 
Mazzotta, M.; Carinci, F. microRNA expression profiling of oral carcinoma identifies new 
markers of tumor progressione. Int. J. Immunopathol. Pharmacol. 2010, 23, 1229–1234. 
34. Tran, M.; McLean, T.; Zhang, X.; Zhao, C.J.; Thomson, J.M.; O’Brien, C.; Rose, B. microRNA 
expression profiles in head and neck cancer cell lines. Biochem. Biophys. Res. Commun. 2007, 
358, 12–17. 
35. Wiklund, E.D.; Gao, S.; Hulf, T.; Sibbritt, T.; Shalima, N.; Costea, D.E.; Villadsen, S.B.; 
Bakholdt, V.; Bramsen, J.B.; Sørensen, J.A.; et al. microRNA alterations and associated aberrant 
DNA methylation patterns across multiple sample types in oral squamous cell carcinoma.  
PLoS One 2011, 6, e27840. 
36. Wong, T.S.; Liu, X.B.; Wong, B.Y.; Ng, R.W.; Yuen, A.P.; Wei, W.I. Mature miR-184 as 
potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin. Cancer Res. 2008, 
14, 2588–2592. 
37. Xiao, W.; Bao, Z.X.; Zhang, C.Y.; Zhang, X.Y.; Shi, L.J.; Zhou, Z.T.; Jiang, W.W. Upregulation 
of miR-31 is negatively associated with recurrent/newly formed oral leukoplakia. PLoS One  
2012, 7, e38648. 
38. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. microRNA-21 
regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. 
Gastroenterology 2007, 133, 647–658. 
39. Frankel, L.B.; Christoffersen, N.R.; Jacobsen, A.; Lindow, M.; Krogh, A.; Lund, A.H. 
Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in 
breast cancer cells. J. Biol. Chem. 2008, 283, 1026–1033. 
40. Darido, C.; Georgy, S.R.; Wilanowski, T.; Dworkin, S.; Auden, A.; Zhao, Q.; Rank, G.; 
Srivastava, S.; Finlay, M.J.; Papenfuss, A.T.; et al. Targeting of the tumor suppressor GRHL3  
by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis.  
Cancer Cell 2011, 20, 635–648. 
41. Wong, T.S.; Man, O.Y.; Tsang, C.M.; Tsao, S.W.; Tsang, R.K.; Chang, J.Y.; Ho, W.K.; Wei, W.I.; 
To, V.S. microRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through 
downregulating c-Myc expression. J. Cancer Res. Clin. Oncol. 2011, 137, 415–422. 
42. Chin, L.J.; Ratner, E.; Leng, S.G.; Zhai, R.H.; Nallur, S.; Babar, I.; Muller, R.U.; Starka, E.; Su, L.; 
Burki, E.A.; et al. A SNP in a let-7 microRNA complementary site in the KRAS 3’ untraslated 
region increases non-small cell lung cancer risk. Cancer Res. 2008, 68, 8535–8540. 
43. Poeta, M.L.; Manola, J.; Goldwasser, M.A.; Forastiere, A.; Benoit, N.; Califano, J.A.; Ridge, J.A.; 
Goodwi, J.; Kenady, D.; Saunders, J.; et al. TP53 mutations and survival in squamous-cell 
carcinoma of the head and neck. N. Engl. J. Med. 2007, 357, 2552–2561. 
Molecules 2014, 19 5715 
 
44. Ganci, F.; Sacconi, A.; Bossel Ben-Moshe, N.; Manciocco, V.; Sperduti, I.; Strigari, L.; Covello, R.; 
Benevolo, M.; Pescarmona, E.; Domany, E.; et al. Expression of TP53 mutation-associated 
microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.  
Ann. Oncol. 2013, 24, 3082–3088. 
45. Harris, T.; Jimenez, L.; Kawachi, N.; Fan, J.; Chen, J.; Belbin, T.; Ramnauth, A.; Loudig, O.; 
Keller, C.E.; Smith, R.; et al. Low-level expression of miR-375 correlates with poor outcome and 
metastasis while altering the invasive properties of head and neck squamous cell carcinomas.  
Am. J. Pathol. 2012, 180, 917–928. 
46. Gee, H.E.; Camps, C.; Buffa, F.M.; Patiar, S.; Winter, S.C.; Betts, G.; Homer, J.; Corbridge, R.; 
Cox, G.; West, C.M.; et al. Has-miR-210 is a marker of tumor hypoxia and a prognostic factor in 
head and neck cancer. Cancer 2010, 116, 2148–2158. 
47. Park, N.J.; Zhou, H.; Elashoff, D.; Henson, B.S.; Kastratovic, D.A.; Abemayor, E.; Wong, D.T. 
Salivary microRNA: Discovery, characterization, and clinical utility for oral cancer detection. 
Clin. Cancer Res. 2009, 15, 5473–5477. 
48. Liu, C.J.; Lin, S.C.; Yang, C.C.; Cheng, H.W.; Chang, K.W. Exploiting salivary miR-31 as a 
clinical biomarker of oral squamous cell carcinoma. Head Neck 2012, 34, 219–224. 
49. Liu, C.J.; Kao, S.Y.; Tu, H.F.; Tsai, M.M.; Chang, K.W.; Lin, S.C. Increase of microRNA  
miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010, 16, 360–364. 
50. Clague, J.; Lippman, S.M.; Yang, H.; Hildebrandt, M.A.; Ye, Y.; Lee, J.J.; Wu, X. Genetic 
variation in microRNA genes and risk of oral premalignant lesions. Mol. Carcinog. 2010, 49, 
183–189. 
51. Yu, Z.; Zhong, L.; Zhang, P.; Chen, W.; Zhang, C. microRNAs contribute to the chemoresistance 
of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol. 2010, 46, 317–322. 
52. Meng, F.; Henson, R.; Lang, M.; Wehbe, H.; Maheshwari, S.; Mendell, J.T.; Jiang, J.; 
Schmittgen, T.D.; Patel, T. Involvement of human micro-RNA in growth and response to 
chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130, 2113–2129. 
53. Yang, H.; Kong, W.; He, L.; Zhao, J.J.; O’Donnell, J.D.; Wang, J.; Weham, R.M.; Coppola, D.; 
Kruk, P.A.; Nicosia, S.V.; et al. microRNA expression profiling in human ovarian cancer:  
miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68, 
425–433. 
54. Niemoeller, O.M.; Niyazi, M.; Corradini, S.; Zehentmayr, F.; Li, M.; Lauber, K.; Belka, C. 
microRNA expression profiles in human cancer cells after ionizing radiation. Radiat. Oncol. 
2011, 6, 29. 
55. Qu, C.; Liang, Z.; Huang, J.; Zhao, R.; Su, C.; Wang, S.; Wang, X.; Zhang, R.; Lee, M.; Yang, H. 
miR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting 
PTEN. Cell Cycle 2012, 11, 785–796. 
56. Shiiba, M.; Shinozuka, K.; Saito, K.; Fushimi, K.; Kasamatsu, A.; Ogawara, K.; Uzawa, K.;  
Ito, H.; Takiguchi, Y.; Tanzawa, H. microRNA-125b regulates proliferation and radioresistance of 
oral squamous cell carcinoma. Br. J. Cancer 2013, 108, 1817–1821. 
57. Janssen, H.L.A.; Reesink, H.W.; Lawitz, E.J.; Zeuzem, S.; Rodriquez-Torres, M.; Patel, K.;  
van der Meer, A.; Patick, A.K.; Chena, A.; Zhou, Y. Treatment of HCV infection by targeting 
microRNA. N. Engl. J. Med. 2013, 368, 1685–1694. 
Molecules 2014, 19 5716 
 
58. Mirna Therapeutics, Inc. A Multicenter Phase I Study of MRX34, microRNA miR-RX34 
Liposome Injectable Suspension. U.S. National Institutes of Health, October 2013. Available 
online: http://www.clinicaltrials.gov/ct2/show/NCT01829971 (accessed on 30 April 2014). 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
